Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 -2.10%90 EBITDA Margin % is 29.74% as of Mar. 2026, which is 8% above its 10-year median of 27.53. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,934.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Mankind Pharma ranks better than 81.46% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mankind Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹10,240 Mil. Mankind Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹34,429 Mil. Therefore, Mankind Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 29.74%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mankind Pharma EBITDA Margin % Related Terms
Mankind Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543904 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a EBITDA Margin % of 29.74% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 27.53. Over the past decade, Mankind Pharma's EBITDA Margin % has ranged from 23.29 to 29.45. According to the industry distribution chart, Mankind Pharma ranks #178 out of 960 companies in the Drug Manufacturers industry, placing it in the top 18.5%.
Is Mankind Pharma's EBITDA Margin % too high?
Mankind Pharma's current EBITDA Margin % of 29.74% is near median its 10-year median of 27.53. Over the past 10 years, this metric has ranged from a low of 23.29 to a high of 29.45. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Mankind Pharma's value of 29.74% is 137.6% above this industry median. Based on the distribution chart, Mankind Pharma ranks #178 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #178 out of 960 companies for EBITDA Margin %. This places Mankind Pharma in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Mankind Pharma's value of 29.74% is 137.6% above this benchmark. Historically, Mankind Pharma's own EBITDA Margin % has ranged from 23.29 to 29.45 over the past decade. While the company's 10-year median is 27.53 vs. the industry median of 12.52, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current EBITDA Margin % of 29.74% is 137.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current EBITDA Margin % is 29.74%, which is near median its own 10-year median of 27.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current EBITDA Margin % is 29.74%, which is near median its 10-year median of 27.53 and 137.6% above the Drug Manufacturers industry median of 12.52. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current EBITDA Margin % is 29.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
EBITDA Margin %: 29.74% (near median its 10-year median of 27.53)
GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
Industry Position: 137.6% above the Drug Manufacturers median (#178 of 960)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
